Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,80
KB0,17
PKN68,4468,471,17
Msft401,52401,560,61
Nokia3,3333,47554,20
IBM182,91182,950,76
Mercedes-Benz Group AG74,3174,320,07
PFE26,4826,491,87
22.04.2024 20:14:47
Indexy online
AD Index online
select
AD Index online
 

  • 22.04.2024 20:13:44
Amarin Depository Receipt (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,875 1,83 0,02 500 728
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.04.2024
Popis společnosti
Obecné informace
Název společnostiAmarin Corporation plc (ADR)
TickerAMRN
Kmenové akcie:ADR
RICAMRN.O
ISINUS0231112063
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 275
Akcie v oběhu k 23.02.2024 401 870 067
MěnaUSD
Kontaktní informace
UliceGemini House, Bartholomews Walk
MěstoDUBLIN
PSČFK7 9JQ
ZeměIreland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon35 316 699 020

Business Summary: Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Amarin Corporation plc (ADR) revenues decreased 17% to $306.9M. Net loss decreased 44% to $59.1M. Revenues reflect SubTotal decrease of 22% to $285.3M. Lower net loss reflects Selling/General/Admin. Expense decrease of 34% to $187.4M (expense), Stock based compensation expense decrease of 44% to $12.5M (expense), Interest income increase from $2.8M to $11.9M (income).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 22.04.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorPatrick Holt5118.07.202318.07.2023
Chief Financial Officer, Executive Vice President, Global Head of HR, Principal Accounting OfficerThomas Reilly5201.08.202320.06.2022
President - Research and Development, Executive Vice President, Chief Scientific OfficerStephen Ketchum5916.02.2012
Executive Vice President, Chief Legal and Compliance Officer, SecretaryJonathan Provoost5415.11.202315.11.2023
Executive Vice President, President - USAaron Berg6118.07.202304.02.2014